Generate Biomedicines (NASDAQ:GENB) Reaches New 1-Year High – Should You Buy?

Generate Biomedicines Inc (NASDAQ:GENB) shares hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $16.79 and last traded at $16.2890, with a volume of 484229 shares changing hands. The stock had previously closed at $15.43.

Wall Street Analysts Forecast Growth

Several analysts have commented on GENB shares. Zacks Research raised shares of Generate Biomedicines to a “hold” rating in a research note on Wednesday, March 25th. The Goldman Sachs Group began coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set a “buy” rating and a $26.00 price objective on the stock. Morgan Stanley upped their target price on Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. Guggenheim initiated coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They set a “buy” rating and a $30.00 target price on the stock. Finally, HC Wainwright raised their price target on Generate Biomedicines from $16.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $25.40.

Generate Biomedicines Trading Down 0.3%

The company’s fifty day simple moving average is $13.68.

Generate Biomedicines (NASDAQ:GENB) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.